Analyst Ratings For Anavex Life Sciences (NASDAQ:AVXL)
Today, Roth Capital initiated coverage on Anavex Life Sciences (NASDAQ:AVXL) with a Buy with a price target of $6.00.
Some recent analyst ratings include
- 3/8/2018-Roth Capital initiated coverage with a Buy rating.
- 2/21/2018-Noble Financial Reiterated Rating of Buy.
- 10/5/2016-FBR & Co Reiterated Rating of Outperform.
Recent Insider Trading Activity For Anavex Life Sciences (NASDAQ:AVXL)
Anavex Life Sciences (NASDAQ:AVXL) has insider ownership of 11.60% and institutional ownership of 22.77%.
- On 3/5/2018 Christopher U Missling, CEO, bought 1,500 with an average share price of $2.63 per share and the total transaction amounting to $3,945.00.
- On 3/2/2018 Christopher U Missling, CEO, bought 1,650 with an average share price of $2.41 per share and the total transaction amounting to $3,976.50.
- On 10/24/2017 Christopher U Missling, CEO, bought 375 with an average share price of $4.92 per share and the total transaction amounting to $1,845.00.
- On 10/19/2017 Christopher U Missling, Insider, bought 375 with an average share price of $4.49 per share and the total transaction amounting to $1,683.75.
- On 10/17/2017 Christopher U Missling, Insider, bought 375 with an average share price of $4.27 per share and the total transaction amounting to $1,601.25.
- On 10/13/2017 Christopher U Missling, Insider, bought 750 with an average share price of $4.22 per share and the total transaction amounting to $3,165.00.
- On 10/5/2017 Christopher U Missling, Insider, bought 375 with an average share price of $4.30 per share and the total transaction amounting to $1,612.50.
Recent Trading Activity for Anavex Life Sciences (NASDAQ:AVXL)
Shares of Anavex Life Sciences closed the previous trading session at 3.14 up +0.25 8.67% with 3.2200000286102295 shares trading hands.
